News Wire

The Centers for Disease Control and Prevention (CDC) has added the U.S. Virgin Islands and Dominican Republic  to its Zika virus travel alerts. Previously, the agency issued an alert for people traveling to the following regions and countries where Zika virus transmission is ongoing: the Commonwealth…
In 2009, HealthCare Partners Affiliates Medical Group, based in Southern California, launched House Calls, an in-home program that provides, coordinates, and manages care primarily for recently discharged high-risk, frail, and psychosocially compromised patients. The program’s aim is to reduce preventable…
The U.S. Preventive Services Task Force (USPSTF) has released a final recommendation statement on screening for depression in adults. The task force found evidence that screening in the primary care setting is beneficial and recommends that clinicians screen all adults for depression. The recommendation…
Results have been announced from the LUX-Lung 7 trial. Superiority in progression-free survival (PFS) and time to treatment failure was demonstrated with the second-generation epidermal growth factor receptor (EGFR)-directed therapy afatinib (Gilotrif, Boehringer Ingelheim) compared with first-generation…
The FDA has accepted for review a biologics license application for IVIG-SN (human normal immunoglobulin G for intravenous administration, Green Cross Corporation) intended for the treatment of primary immunodeficiency diseases (PIDs). The Prescription Drug User Fee Act (PDUFA) date for the FDA to complete…
The World Health Organization has announced that Zika virus infection, a mosquito-borne illness that in the past year has swept quickly throughout equatorial countries, is expected to spread across the Americas and into the U.S. The symptoms of the disease include a rash, headache, and mild fever. However,…
The FDA has accepted for review the biologics license application (BLA) for ABP 501 (Amgen), a biosimilar candidate to adalimumab (Humira, AbbVie). The BLA, submitted on November 25, 2015, is based on analytical, clinical, and pharmacokinetic data. Phase 3 comparative efficacy and safety studies were…
A woman’s heart attack may have different underlying causes, symptoms, and outcomes compared with men, and differences in risk factors and outcomes are further pronounced in black and Hispanic women, according to a scientific statement from the American Heart Association (AHA). The statement, published…
Naturally occurring clay from British Columbia, Canada –– long used by the region's Heiltsuk First Nation for its healing potential –– exhibits potent antibacterial activity against multidrug-resistant pathogens, according to researchers at the University of British Columbia. The team recommends…
Five years after its launch, the Re-Engineered Discharge (RED) protocol is struggling to catch on in the nation’s hospitals, according to a report from HealthLeaders Media. The creators of the 12-step discharge protocol, which took seven years to compile, say it reduces readmissions and saves money,…
In October 2015, the Centers for Medicare and Medicaid Services (CMS) announced that more than 1,600 participants had entered its Bundled Payment for Care Improvement (BPCI) program, including 415 acute-care hospitals, 305 physician groups, and 723 skilled-nursing facilities. In November, the CMS released…
Emergency departments (EDs) are health care’s front line — in the U.S., nearly 45 out of 100 people visit an ED in any given year. But there is an issue brewing behind the scenes in emergency medical facilities, one that can’t be fixed by a simple stitch or bandage, according to an article in…
The FDA has accepted a supplemental new drug application for empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) based on cardiovascular (CV) risk-reduction data from the landmark EMPA-REG OUTCOME trial. A decision from the FDA is expected within the standard review time frame. Cardiovascular…
OncoMed Pharmaceuticals has announced an update on its phase 2 ALPINE trial of the pancreatic cancer drug tarextumab after a preplanned interim efficacy assessment by an independent data safety monitoring board (DSMB). The DSMB evaluated data from 172 patients treated as of a data cutoff date of January…
The FDA has approved nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma. Both drugs are marketed by Bristol-Myers Squibb. This approval expands the original indication for…

Pages